Join Our Whitelist
Our Vision & Solution
At SCI, we are devoted to the international research, development, and implementation of stem cell therapy. We are also expanding our network with professionals, labs, clinics, hospitals, and nonprofit organizations. Our ultimate goal at SCI is to connect people who need treatment with the right dedicated solutions and professionals for their unique needs. At SCI, we believe such connections should be convenient and at your fingertips, just as so many other services are in modern society. We imagine a world where each and every person, no matter where they come from, will be able to connect with a Stem Cell Specialist instantly through our Stem Cell Innovations application (SCI Application), and in the same connection be able to decide when and how much confidential information to share with professionals.
SCI’s goal is to raise a maximum of $36,000,000 and a minimum of $3,000,000. Some of these numbers may change with ETH/ USD exchange rates and volatility throughout the ICO and launch phase of the company’s growth. This document is based on exchange rate estimates at the time of writing. SCI will mint a total of 800 million tokens. Of these, 240 million tokens will be available during the token sale to start on September 17th, 2018.
Each token will be sold at $0.15. Should all 240 million tokens be sold, the raised funds will be $36,000,000. Tokens unsold from the 240 million will be burned. The funds raised during the token sale are to be used per the project roadmap above.
Pre-Sale from 17th September 2018 0800 HRS UTC/GMT to 29th October 2018 2359 HRS UTC/GMT. Main-Sale from 21st November 2018 0800 HRS UTC/GMT to 17th Janurary 2019 2359 HRS UTC/GMT.
The total number of tokens sold during the pre-sale period cannot exceed 60% of the total number of tokens initially put up for sale by the Main-Sale. If the number of requests received during the pre-sale period exceeds, request will be honored in the chronological order in line with the set limit, and excess orders will be returned to clients.
Establishment of Camden RAD, LLC, a company devoted to stem cell research and development.-COMPLETED-
Attended Token 2049 conference in Hong Kong. Attended Stem Cell Summit at the University of California in Los Angeles (UCLA). Attended CBC conference in San Francisco, CA.-COMPLETED-
Whitelist is scheduled to go live. Token Sale starts.
SCI will begin final testing and reporting based on blockchain technology being used.
Creation of a non-identical patient identification factor on Passive Blockchain Node will be initialized.
Demo testing for SCI Application
v 1.0 will begin.
Release of Market Surveillance strategy for further growth Release SCI Application v2.0 Enrollment begins for professionals, patients, and stem cell laboratories in Middle East and across North Africa. Announcement of first SCI Lab location and franchise expansion plan.
Stem Cell Lab Evaluation report per first year of operation and development. Release SCI earnings and financials report. Release results of SCI's stem cell research and development to date.
Begin second phase of SCI stem cell research and development. Release SCI Application v3.5, including professional-facing component to help practitioners become more involved in the stem cell research space and contribute to the network.
Release SCI earnings and financials report for second year operation and development. Release public update on SCI stem cell research and development. Stem Cell Lab Evaluation report for second year.
Camden RAD, LLC is rebranded as Stem Cell Innovations, and a new company is established, based on blockchain technology. Advanced research begins to determine market and development opportunities.-COMPLETED-
Attended ICO20 Summit in Santa Monica, CA. Integration of smart contract technology is established. Company headquarters incorporated in Gibraltar, GB. Strategic efforts toward development begins. Interviews with potential medical participants take place.-COMPLETED-
Token Sale ends and min max caps are assessed. Distribution of Tokens to participants through ERC20 will commence.
Release of the SCI Application v1.1 Enrollment begins for doctors, patients, and stem cell laboratories in the United States
Announcement of clinical development and research strategy in the stem cell field. Public announcement regarding SCI achievements to date. First ever online synthetic stem cell purchase through the SCI Application. Release SCI Application v3.0, fully functional platform for professionals and patients.
Expansion of SCI stem cell labs and clinics in China, Japan, South Korea, and India. Begin charging membership fees (payable in Stem Cell Innovations tokens) for professional-facing portion of SCI application.
Expansion and acquisition of SCI stem cell labs and clinics in Europe.
Release SCI Application v4.0 including: A new platform for medical students, universities, and hospitals to engage with the SCI Application. Fully Functional EMR Worldwide Enforcing HIPPA and expanding of synthetic stem cell delivery to Latin America.
Chief Executive Officer / FounderMoe Galal
Moe is a founder of SCI, and hopes to usher in the next generation of medicine using stem cells and other technological advancements relying on his 20+ years of experience in business.
Chief Operations Officer / Co-FounderBen Barel
With more than twenty years of progressive corporate healthcare managing operations experience. Carrying demonstrated track record of driving margin improvement and operational efficiency.
Chief Technology Officer / Co-FounderAli Alrashidi
A background rich in programming and development, Ali manages SCI’s blockchain platform. Ali’s support in furthering academic research in the field of blockchain will allow SCI to grow.
Chief of Staff / Co-FounderMatt Galal
Matt has over 15 years of experience as successful entrepreneur and is driven by success while taking a detail-oriented approach to everything he does.
Operations Engineer / Co-FounderKobi Barel
With years of experience in the technology sector, Kobi quickly recognized the power of blockchain, radiology, and stem cell technologies could have on the health industry with SCI.
Medical DirectorJohn Glavinovich, M.D.
With over 30 years’ experience in hospital-related clinical, management and operational practices, Dr. Glavinovich a non-traditional approach to the work being done by the team.
Health Informatics ManagerPhilip Glukhovsky, D.C.
Dr. Glukhovsky has been involved in the development of important genetic testing for blood and multiple other diseases.
VP of MarketingRoger Williams
Roger is known for his innovative approach to marketing and his experience will greatly benefit SCI as the company expands it network and services in the stem cell industry.
VP, PR & Corporate CommunicationsLiz Curlett
Liz brings 20 years of project management experience to the team, 10 of which is working with technology start up's.
Business DevelopmentCandice Kouchache
Candice brings over 10 years’ experience to the SCI team to develop internal practices, resources, and client support measures and more.
VP of International Human ResourcesAhmed Elsantawi
Ahmed’s 15 years’ experience in Human Resources allows the company to ensure the organization grows in a sustainable and efficient way.
Web DesignerDavid Marmon
The brains behind the SCI website and development, David’s experience in design and programming will help SCI present a professional image and brand.
Heather is an experienced copywriter with an extensive background in adult learning, technology, and management and works with the team at SCI to get the words just right.
Creative WriterEverlecia Taylor
Everlecia plays a pivotal part in digital branding of SCI through engaging content and copy across all of SCI’s media platforms.
Administrative ManagerMarina Evglevskaya
Marina’s focus as an Administrative Manager is to ensure that the company’s processes run smoothly while relying on her many years of experience.
Product ManagerRakel Apodaca
Rakel Apodaca, Founder of Revive A Cell Biotechnology, is a proud United States Air Force Veteran. One of Miss Apodaca’s sought after missions are to donate Stem Cell Therapy to injured military personnel and Veterans in need.
Michelle Aragon works as an International Business developer for Revive A Cell Biotechnology. Michelle has been a Medical Manager for surgery centers for over 30 years.
Boyan is the Founder & CEO of Mogul Media, JOSIC Media, and the leading ICO management platform, ICODashboard.io. Boyan has been involved as an advisor on numerous ICO and blockchain projects including Aeron, SignIX, Velix.ID, Cashbag, Luckbox, BlockTrics, Stem Cell Innovations, BountyMissions, Blockchain Media, BloxKapital, GoFind, CryptoChats and Energy Premier.
Marc X. Ellul
Marc X. Ellul has 25 years’ experience as a Gibraltar lawyer. He is the Managing Partner of Ellul & Co. and heads the firm’s fintech team.
Roger Shortz, M.D.
Dr. Shortz is a board certified neurosurgeon with decades of experience. He has advanced training and interest in minimally invasive spinal surgery, as well as complicated spinal instrumentation and fusion.
Greg Maddex, D.O
Dr. Greg Maddex is an esteemed advisor to the team at SCI. He has proudly practiced a variety of holistic measures in his extensive 30 year career that have brought him on board with the Stem Cell Innovations team.
Pantea Nakieen, M.D.
Dr. Nakieen is a successful healthcare services professional with a doctorate in Chiropractics from Southern California University of Health Sciences.
Shahab is a pharmacist and owner of Woodland Hills Rx Pharmacy, where he provides individualized and thorough services to his customers.
As the CEO of Shopping Cart Elite Igor leads over 250+ employees across seven divisions. He is the cofounder of rek9, which recently rolled out bcdbazaar.com for Bitcoin Diamond, the first ecommerce crypto store, and he is the marketing director for Bitcoin Gold leading the btgpay initiative.